ZW24481A1 - Aminoalky furan derivative - Google Patents

Aminoalky furan derivative

Info

Publication number
ZW24481A1
ZW24481A1 ZW244/81A ZW24481A ZW24481A1 ZW 24481 A1 ZW24481 A1 ZW 24481A1 ZW 244/81 A ZW244/81 A ZW 244/81A ZW 24481 A ZW24481 A ZW 24481A ZW 24481 A1 ZW24481 A1 ZW 24481A1
Authority
ZW
Zimbabwe
Prior art keywords
aminoalky
furan derivative
furan
derivative
aminoalky furan
Prior art date
Application number
ZW244/81A
Other languages
English (en)
Inventor
Derek Leslie Crookes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZW24481(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZW24481A1 publication Critical patent/ZW24481A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
ZW244/81A 1980-10-01 1981-10-01 Aminoalky furan derivative ZW24481A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01

Publications (1)

Publication Number Publication Date
ZW24481A1 true ZW24481A1 (en) 1983-04-27

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
ZW244/81A ZW24481A1 (en) 1980-10-01 1981-10-01 Aminoalky furan derivative

Country Status (29)

Country Link
US (2) US4521431A (enExample)
JP (1) JPS5791983A (enExample)
KR (1) KR870001431B1 (enExample)
AT (1) AT389696B (enExample)
AU (1) AU549119B2 (enExample)
BE (1) BE890574A (enExample)
CA (1) CA1202638A (enExample)
CH (1) CH652122A5 (enExample)
CZ (1) CZ280885B6 (enExample)
DE (1) DE3139134A1 (enExample)
DK (2) DK167794B1 (enExample)
ES (1) ES505951A0 (enExample)
FR (1) FR2491067A1 (enExample)
GR (1) GR72499B (enExample)
HK (1) HK97985A (enExample)
IE (1) IE51604B1 (enExample)
IL (1) IL63968A (enExample)
IT (1) IT1143237B (enExample)
KE (1) KE3549A (enExample)
LU (1) LU83661A1 (enExample)
MY (1) MY8500747A (enExample)
NL (1) NL8104482A (enExample)
NZ (1) NZ198522A (enExample)
PH (2) PH19489A (enExample)
PT (1) PT73744B (enExample)
SE (1) SE453500B (enExample)
SK (1) SK403591A3 (enExample)
ZA (1) ZA816809B (enExample)
ZW (1) ZW24481A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1384197A3 (ru) * 1983-07-15 1988-03-23 Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие) Способ получени 1- @ 2-(5-(ди-метиламинометил)-2-(фурилметилтио)-этил) @ амино-1-(метиламино)-2-нитроэтилена или его гидрохлорида и способ получени дигидрохлорида 2-(2-аминоэтил)-тиометил-5-(диметиламинометил)-фурана или его моногидрохлорида
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
AU694419B2 (en) * 1993-03-12 1998-07-23 Zoetis P&U Llc Crystalline ceftiofur free acid
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
EP0754182A1 (en) * 1994-04-08 1997-01-22 Brantford Chemicals Inc. Form 1 ranitidine hydrochloride with increased density
CN1147253A (zh) 1994-04-15 1997-04-09 法玛西雅厄普约翰公司 新晶型的1-[5-甲亚磺酰氨基吲哚基-2-羰基]-4-[3-(1-甲基乙基氨基)-2-吡啶基]哌嗪
IN181698B (enExample) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181699B (enExample) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
FI964565A7 (fi) * 1994-05-18 1996-11-14 Aventis Pharma Inc Menetelmiä antihistamiinisten piperidiinijohdosten vedettömien ja hydr atoituneiden muotojen, niiden polymorfien ja pseudomorfien, valmistami seksi
ES2122387T3 (es) 1994-06-24 1998-12-16 Ranbaxy Lab Ltd Procedimiento para la preparacion de la forma 1 del clorhidrato de ranitidina.
MX9703622A (es) * 1994-11-18 1997-08-30 Upjohn Co Una nueva forma solida fisicamente estable en una fluoroquinolona.
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
PT903345E (pt) 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) * 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US7094799B2 (en) * 2002-11-08 2006-08-22 Dov Pharmaceutical, Inc. Polymorphs of bicifadine hydrochloride
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
CN101272781A (zh) 2005-07-27 2008-09-24 多夫药品公司 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
CA2667416C (en) * 2006-10-20 2013-12-17 Scinopharm Singapore Pte, Ltd. Process for making crystalline anhydrous docetaxel
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
AU2012276650B2 (en) * 2011-06-30 2016-06-23 Toray Industries, Inc. Crystals of glycine derivative and pharmaceutical use thereof
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN106432148B (zh) * 2015-05-26 2018-04-17 烟台市华文欣欣医药科技有限公司 一种治疗胃病的药物盐酸雷尼替丁化合物的制备方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES8301954A1 (es) 1983-01-01
BE890574A (fr) 1982-04-01
DK167794B1 (da) 1993-12-13
AT389696B (de) 1990-01-10
DE3139134C2 (enExample) 1990-04-19
US4672133A (en) 1987-06-09
MY8500747A (en) 1985-12-31
JPS5791983A (en) 1982-06-08
PH19489A (en) 1986-05-14
LU83661A1 (fr) 1983-06-08
PH21761A (en) 1988-02-18
HK97985A (en) 1985-12-13
SE453500B (sv) 1988-02-08
IL63968A (en) 1985-10-31
SK277922B6 (en) 1995-08-09
PT73744A (en) 1981-10-01
IT8149407A0 (it) 1981-10-01
DK436281A (da) 1982-04-02
SK403591A3 (en) 1995-08-09
AU7595581A (en) 1982-04-08
ATA422281A (de) 1989-06-15
CZ280885B6 (cs) 1996-04-17
KR830007070A (ko) 1983-10-14
DK33792A (da) 1992-03-12
CZ403591A3 (en) 1994-01-19
IE812287L (en) 1982-04-01
DK33792D0 (da) 1992-03-12
ZA816809B (en) 1983-05-25
NZ198522A (en) 1985-07-12
CA1202638A (en) 1986-04-01
GR72499B (enExample) 1983-11-15
ES505951A0 (es) 1983-01-01
FR2491067A1 (fr) 1982-04-02
KR870001431B1 (ko) 1987-08-06
DE3139134A1 (de) 1982-05-19
AU549119B2 (en) 1986-01-16
NL8104482A (nl) 1982-05-03
FR2491067B1 (enExample) 1984-09-07
SE8105812L (sv) 1982-04-02
US4521431A (en) 1985-06-04
PT73744B (en) 1983-10-31
KE3549A (en) 1985-08-16
JPH0443070B2 (enExample) 1992-07-15
IE51604B1 (en) 1987-01-21
CH652122A5 (fr) 1985-10-31
DK167923B1 (da) 1994-01-03
IL63968A0 (en) 1981-12-31
IT1143237B (it) 1986-10-22

Similar Documents

Publication Publication Date Title
ZW24481A1 (en) Aminoalky furan derivative
GB2079270B (en) Imidazo-rifamycin derivatives
GB2086380B (en) L-argininal derivatives
JPS5785379A (en) 3-aryl-5-isothiazole derivative
JPS56150050A (en) Oxitocin derivative
PT72965A (en) 4-alkylphenylpropylamine derivatives
GB2091719B (en) Benzofuran derivatives
JPS5781476A (en) Isooxazolylbenzamide derivative
GB2075499B (en) Nonaprenylamine derivatives
GB2083462B (en) 2-thiopenem derivatives
GB2088365B (en) Moranoline derivative
GB2067989B (en) Bis-moranoline derivatives
PH18633A (en) Novel antrancyclinone derivative
GB8324990D0 (en) 3-aminopropoxyphenyl derivatives
PH16930A (en) Phenoxy-aminopropanol derivatives
ZW9881A1 (en) Substituted phenoxyaminopropanol derivatives
JPS577467A (en) Novel phenylpropargylamine derivative
DE3165137D1 (en) Thiophene derivatives
GB2088379B (en) 1-phenethylimidazole derivatives
GB2076815B (en) Aminophenylpyridine derivatives
GB2085882B (en) Aprosamine derivatives
JPS5793949A (en) Alpha-cyanophenoxybenzylamine derivative
GB2076395B (en) Nonaprenylamine derivatives
GB2070589B (en) 7a1methoxycephalospin derivatives
GB2074165B (en) Nonaprenylamine derivatives